Back to dashboard
Traditional MedicareCoverageMedium impact

MolDX: Molecular Testing for Solid Organ Allograft Rejection

Medicare/CMS - LCD·Transplant Surgery, Nephrology·Local Coverage Determination
Effective date
Not stated
We identified it
Sep 3, 2026
Days to comply
—

Summary

This policy (L38629) for MolDX molecular testing related to solid organ allograft rejection has been RETIRED as of 8/29/2026. This is a discontinued local coverage determination that is no longer in effect. Billing teams should verify current coverage guidance with Noridian Healthcare Solutions, as this policy no longer applies.

Action Required

Action needed
By 9/15/2024: Billing team must verify with Noridian Healthcare Solutions (MAC Part A and Part B) the current coverage policy for molecular testing for solid organ allograft rejection, as LCD L38629 is retired. Do not reference or apply this retired policy to new claims. Contact Noridian directly to obtain the replacement or current guidance. Failure to use current policy may result in claim denials or delays.

Related policy hubs